Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Hits First Milestone in miRNA Inflammatory Disease Deal with GlaxoSmithKline


Regulus Therapeutics today announced that it has successfully delivered microRNA inhibitors into mice and identified changes in target gene expression in their immune cells, reaching the first discovery milestone in its collaboration with GlaxoSmithKline.

"This milestone is further evidence that microRNAs represent disease targets whose therapeutic modulation could revolutionize the way we treat immune diseases," Regulus CSO Peter Linsley said in a statement. "We are particularly pleased that this has been achieved in the first year of the collaboration."

The development is the fruit of a deal the companies signed about a year ago to discover, develop, and market microRNA-based therapeutics for inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease (see RNAi News, 4/17/2008).

Under the arrangement, Regulus will develop antagonists to four miRNA targets related to inflammatory disease from discovery through completion of clinical proof of concept. GlaxoSmithKline has an exclusive option to license product candidates directed at the four targets.

In exchange, Regulus will receive $20 million upfront from GlaxoSmithKline, which includes a $15 million option fee and a $5 million note that will convert into Regulus stock in the future under certain undisclosed circumstances.

Regulus could also receive up to $144.5 million in development, regulatory, and sales milestones, as well as tiered royalties up to double-digit percentages on the sale of products resulting from the alliance.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.